Research status on immunotherapy trials of gastric cancer

Table 1 Current clinical trial results of immune checkpoint inhibitors for gastric cancer

Ref.	Trial phase	Cancer type	n	Drug(s) tested	Key outcome	Trial name (NCT)
Kawazoe et al[15], 2020	2	GC	29	Pembrolizumab + lenvatinib	ORR 69% (95%CI: 49-85) mPFS 7.1 mo (95%CI: 5.4-13.7)	EPOC1706 (NCT03609359)
Kawazoe et al[16], 2020	2b	GC/GEJC	54	Pembrolizumab + SOX	ORR 72.2% (95%CI: 58.4-83.5) mPFS 6.9 mo (95%CI: 5.6-8.3)	KEYNOTE-659 (NCT03382600)
Catenacci et al[17], 2020	1b-2	GEJC	92	Margetuximab + pembrolizumab	ORR 18% (95%CI: 11-28) mPFS 2.73 mo	CP-MGAH22-05 (NCT02689284)
Bang et al[9], 2019	2	GC/GEJC	25	Pembrolizumab + SOC	ORR 60.0% (95%CI: 38.7-78.9) mPFS 6.6 mo (95%CI: 5.9-10.6)	KEYNOTE-059 (NCT02335411)
			31	Pembrolizumab	ORR 25.8% (95%CI: 11.9–44.6) mPFS 3.3 mo (95%CI: 2.0-6.0)
Tabernero et al[10], 2019	3	GC/GEJC	256	Pembrolizumab	ORR 14.5% (95%CI: 10.4-19.4) mPFS 2.0 mo (95%CI: 1.5-2.8)	KEYNOTE-062 (NCT02494583)
			257	Pembrolizumab + SOC	ORR 48.6% (95%CI: 42.4-54.9) mPFS 6.9 mo (95%CI: 5.7-7.3)
			250	Placebo + SOC	ORR 36.8% (95%CI: 30.8-43.1) mPFS 6.4 mo (95%CI: 5.7-7.0)
Boku et al[18], 2019	2	G/GEJ	21	Nivolumab + SOX	ORR 57.1% (95%CI: 34.0-78.2) mPFS 9.7 mo (95%CI: 5.8-NR)	ATTRACTION-4 (NCT02746796)
			18	Nivolumab + CapeOX	ORR 76.5% (95%CI: 50.1-93.2) mPFS 10.6 m0 (95%CI: 5.6-12.5)

GC: Gastric cancer; GEJC: Gastroesophageal junction cancer; SOC: Standard of care; SOX: S-1 plus oxaliplatin; CapeOX: Capecitabine plus oxaliplatin; ORR: Objective response rate; mPFS: Median progression-free survival; CI: Confidence interval.